Jiangsu Kanion Pharmaceutical Co., Ltd. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Jiangsu Kanion Pharmaceutical Co., Ltd. with three other
companies in this sector in China:
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
sales of 2.86 billion Chinese Renmimbi [US$415.84 million]
of which 54%
was Medicine Manufacturing),
Guangdong Taiantang Pharmaceutical Co Ltd
(3.07 billion Chinese Renmimbi [US$446.36 million]
Harbin Gloria Pharmaceuticals Co., Ltd
(2.98 billion Chinese Renmimbi [US$433.09 million]
of which 77%
was Pharmaceutical Manufacturing).
During the year ended December of 2016, sales at
Jiangsu Kanion Pharmaceutical Co., Ltd. were 3.00 billion Chinese Renmimbi (US$435.58 million).
increase of 6.4%
versus 2015, when the company's sales were 2.82 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Jiangsu Kanion Pharmaceutical Co., Ltd.
(and since 2011, sales have increased a total of 95%).
Sales of Exportation Trade saw an increase
6.4% in 2016, from
2.82 billion Chinese Renmimbi to 3.00 billion Chinese Renmimbi.
Not all segments of Jiangsu Kanion Pharmaceutical Co., Ltd. experienced an increase in sales in 2016:
sales of Other Operations fell 22.6% to 2.71 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).